fingolimod (gilenya) Report issue

Small molecule Approved FDA First in Class Priority Review FDA

Active Ingredient History

NOW
  • Now
Fingolimod (FTY720) is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod (trade name Gilenya, Novartis) is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system. Fingolimod was approved as a first-in-class, orally active drug for relapsing multiple sclerosis in 2010, and its applications in other disease conditions are currently under clinical trials.   NCATS

More Chemistry

Drug Pricing (per unit)

Australia

$58.4917

United States

$199.4873 - $294.8743
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

fingolimod | fingolimod hcl | fingolimod hydrochloride | fingolimodum | fty-720 | gilenya | gsk618334

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue